Cornbread Hemp has announced its exclusive contract with Alliant Purchasing, a national Group Purchasing Organization (GPO). This partnership positions Cornbread Hemp as the sole supplier of USDA organic CBD products for Accountable Care Organizations (ACOs) within Alliant Purchasing’s network, which includes 68,000 provider locations. These ACOs are designated to participate in the landmark Substance Access Beneficiary Engagement Incentive (BEI) program, administered by the Center for Medicare and Medicaid Innovation (CMMI).
A New Era for Hemp in Medicare
The Centers for Medicare & Medicaid Services (CMS) has been detailing its forthcoming hemp products pilot program, which is slated to begin on April 1, 2026. This initiative will allow eligible Medicare beneficiaries to receive certain hemp-derived products through participating organizations, potentially offering up to $500 in products annually per beneficiary. While Medicare itself will not directly pay for these products, and beneficiaries are not to submit claims for them, the program aims to improve symptom control for participants in specific Innovation Center models.
The eligible hemp products must be federally legal, containing no more than 0.3% delta-9 THC. For orally administered products, the limit is set at 3 milligrams per serving for total tetrahydrocannabinols, excluding inhalable products and non-naturally produced cannabinoids. Inhalable products are specifically excluded from this pilot program.
Navigating Eligibility and Safeguards
To qualify for the BEI program, beneficiaries must generally be at least 18 years old, not meet the model’s frailty exclusion criteria, and not have certain disqualifying conditions. Pregnant or breastfeeding individuals are also excluded. A physician’s assessment of appropriateness, documented through a shared decision-making process, is a prerequisite. This process involves discussing benefits and risks, the beneficiary’s goals and preferences, and a review of current medications and potential interactions.
Participating organizations are responsible for the procurement, ordering, storage, inventory control, and distribution of these hemp products. Products must be provided directly by a qualified physician affiliated with the participating organization, and beneficiaries cannot be instructed to purchase retail products for reimbursement. The pilot program emphasizes product safety and quality, requiring participants to meet federal, state, and local production, quality, and safety laws. Products must be sourced from legally compliant farms, consistent with the 2018 Farm Bill hemp requirements, and undergo testing for cannabinoid content and contaminants.
Industry Reactions and Future Implications
The announcement of the Medicare hemp pilot has generated significant attention, with companies like Charlotte’s Web expressing appreciation for CMS’s approach in expanding access to responsible hemp wellness. However, the initiative has also sparked debate, with some critics questioning whether CMS is circumventing traditional FDA drug approval standards. Concerns have been raised about the discrepancy between the pilot’s THC allowance (3 mg per serving) and upcoming federal legislation that may restrict ingestible hemp products to a much lower threshold (0.4 mg total THC per container).
Despite these discussions, the pilot program is seen as a potentially transformative step, representing the first federal insurance coverage mechanism for cannabis-related therapeutics. This development could set a precedent for broader insurance coverage of cannabis therapeutics in the future and normalize the CBD market, which has faced challenges due to varying state laws and a lack of consistent FDA guidance. The program’s success could lead to expanded access and further research into the benefits of cannabinoids for symptom management, particularly among older adults.
